SCHEMBL3016922

SCHEMBL3016922

COc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(Cl)c([N+](=O)[O-])c3)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
USP2 O75604 2/20 0.51
HSD17B10 Q99714 2/20 0.51
RECQL P46063 1/20 0.51
HSD11B1 P28845 1/20 0.51
VCAM1 P19320 2/20 0.50
NPBWR1 P48145 1/20 0.47
MCHR1 Q99705 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 4/20 0.46
MAPK1 P28482 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HTT P42858 1/20 0.44
POLB P06746 1/20 0.43
GLA P06280 1/20 0.43
TSHR P16473 1/20 0.43
EIF4E P06730 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011334 0.90 MAPT (0.51) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3011185 0.90 MAPT (0.51) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3016751 0.89 MAPT (0.55) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3016510 0.89 VCAM1 (0.53) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3015882 0.87 MAPT (0.54) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3012021 0.87 MAPT (0.54) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3016857 0.86 ALDH1A1 (0.52) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL2999988 0.86 SMN1; SMN2 (0.53) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3014312 0.85 HSD17B10 (0.60) MAPTUSP2HSD17B10RECQLHSD11B1
SCHEMBL3010513 0.85 USP2 (0.57) MAPTUSP2HSD17B10RECQLL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.